Panther Fusion® MRSA Assay

Automate your methicillin-resistant Staphylococcus aureus (MRSA) testing.

Overview

Documents

Training

Detection & Differentiation

The Panther Fusion MRSA assay brings full automation, efficiency and excellent assay performance to MRSA screening by producing accurate and comprehensive results, providing cost efficiencies to the laboratory and allowing for better patient management.¹ The assay detects and differentiates Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swab samples.¹

Panther Fusion automatically interprets and reports the results from the following molecular targets; GAPDH, Mec A/C and OrfX/SCC.

GAPDH

Staphylococcus aureus specific housekeeping gene

Mec A/C

A gene that causes methicillin resistance

OrfX/SCC

Indicates the presence of the cassette

Automate your Testing Routine & Deliver Results Faster

The Panther Fusion MRSA assay leverages the benefits of the Panther Fusion® System, with flexible workflow and improved laboratory efficiency, in comparison to protocols for enrichment followed by culture or LDT.

Rapid Results

Time to first result in 2.4 hours. Five results every 5 mins thereafter. Up to 335 results in 8 hours.¹

Workflow Efficiency

Direct loading of ESwab™ nasal samples, enables fully automated sample to result processing.¹ Load up to 120 samples at one time. Panther Fusion automatically interprets and reports the results.²

Strain Inclusivity & High Differentiation

Invader Plus® chemistry provides qualitative detection and differentiation of SA and MRSA, broad strain inclusivity, including the Bengal Bay clone, and correct identification of empty cassette variants.¹

Low Waste

Unit-dose lyophilised reagents eliminate waste and the need for manual preparation. The ready-to-use, unit-dose format with 60-day onboard stability also helps reduce waste.¹

Download Flashcard

Assay Menu

Technician walking through Panther systems in a lab setting

Simplify & Scale the Future of Diagnostics

The Panther Fusion MRSA assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population-level screening.

Browse Portfolio

Proven Performance

Delivering qualitative detection and differentiation of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus from nasal swab specimens.¹

>95% sensitivity

and specificity for the detection of MRSA

>95% sensitivity

and specificity for the detection of SA

Broad strain inclusivity

including the Bengal Bay clone and detection of empty cassette variants

Panther Fusion MRSA Workflow

Specimen arrives in lab
Replace specimen cap with pierceable cap
Load sample(s) onto Panther Fusion
Load reagents, if required (60 day onboard stability)
Automated Results report: +/- for MRSA & SA

Report results the same day. The time to first result is 2.4 hrs, enabling improved patient management and faster diagnosis.

Lab technician arranging Assay Boxes in lab setting

Elderly woman looking to the left wearing hospital robe

A Highly Invasive Threat

MRSA is considered a significant cause of healthcare-associated infections (HAIs) in the EU.³ As a result of its highly invasive nature and limited susceptibility to treatment, MRSA is an immense clinical burden with high morbidity and mortality.⁴ Due to high prevalence among hospitalised patients, accurate and fast identification of MRSA is necessary to initiate effective antimicrobial therapy and slow the spread of MRSA infections.⁵ Molecular methods for the detection of MRSA have been introduced as a faster alternative to traditional, time-consuming culture methods.

Get Support

All Other Requests

Evidence. Insight. Collaboration.

Our education portal improves patient care through excellence in education, communication of clinical and scientific evidence, and partnerships with the healthcare community.

Visit Portal

Insights

Visit the Hologic Innovation Exchange

FDA Market Authorisation for Genius™ Digital Diagnostics System

Discover the Future of Cervical Cancer Screening

A Vision for Women-centric Care

References

MRSA Assay (Panther Fusion) [Package Insert] AW-22789-001 Rev 001, San Diego, CA; Hologic, Inc., 2023
Panther / Panther Fusion Operators Manual AW-26055-001 Rev. 001
Köck, R., Becker, K., Cookson, B., et al. . Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. 2010 Euro Surveill. 15(41), pii=19688. Available online: http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=19688.
Ventola, C.L. 2015. The antibiotic resistance crisis: Part 1: Causes and threats. Pharm Ther. 40(4):277–283.
Bode, L.G.M., Kluytmans, J.A.J.W., Wertheim, H.F.L., et al. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcusaureus. N Engl J Med. 362(1):9-17.

Documentation